IGM-2644 is a T cell engaging IgM antibody targeting CD38 for the treatment of patients with multiple myeloma. IGM plans to file an IND application in 2022 with the U.S. Food and Drug Administration (FDA) for IGM-2644 to begin clinical testing in multiple myeloma.

< SEE OUR PIPELINE